Global chemicals and ingredients distributor Brenntag has officially launched the commercial availability of BYPHAR, a new biopharma raw material portfolio designed to simplify sourcing, strengthen compliance and support manufacturers from early-stage research through commercial production.
Unveiled globally in April, BYPHAR brings together Brenntag’s distribution network, regulatory expertise and technical services into a single structured offering aimed at helping biopharmaceutical companies navigate increasingly complex manufacturing demands.
The three-tier portfolio has been developed specifically for the biopharma sector, enabling manufacturers to select raw materials based on application criticality, production stage and regulatory requirements.
BYPHAR supports a wide range of biopharmaceutical applications, including monoclonal antibodies (mAbs), recombinant proteins, cell and gene therapies, vaccines, nucleic acid production, antibody-drug conjugates (ADCs), biosimilars and diagnostic manufacturing.
As the industry faces mounting regulatory scrutiny, more complex global supply chains and pressure to accelerate development timelines, manufacturers are demanding greater confidence in raw material quality, traceability and compliance.
Brenntag said BYPHAR addresses these challenges through a regulatory-ready portfolio backed by comprehensive documentation, reliable global supply and technical support.
'BYPHAR represents a major step forward in how we support our biopharma customers," said Gearoid O'Rourke, Senior Director Biopharma, Brenntag Pharma.
"By combining high-quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we are helping customers accelerate development and ensure the highest standards of all manufacturing stages.”
The BYPHAR portfolio is divided into three categories, each aligned with different manufacturing risks and development stages:
BYPHAR Explore supports research, process development and early manufacturing with non-GMP materials for non-critical applications. Products are monograph compliant where applicable and supplied with essential regulatory documentation.
BYPHAR Enhance provides GMP-compliant raw materials suitable across biopharmaceutical manufacturing processes. Produced in line with IPEC and EXCiPACT guidelines, the portfolio includes regulatory documentation designed to support qualification and validation activities.
BYPHAR Excel targets the most critical manufacturing applications, offering LBLE raw materials produced under GMP conditions. Products are multi-compendial where applicable and supported by extensive regulatory documentation to meet demanding quality, compliance and supply assurance requirements.
To further streamline customer access, Brenntag will launch a dedicated customer portal in August, providing product specifications, fact sheets and regulatory documentation packages.
